This inventor holds 4 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: University of California. Active years: 2001-2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001-2003
Title: Kateri A Ahrendt: Innovator in Cancer Treatment
Introduction
Kateri A Ahrendt is an accomplished inventor based in Boulder, CO. He has made significant contributions to the field of cancer treatment through his innovative research and development. Although he currently holds no granted patents, his work in the pharmaceutical industry has been influential.
Latest Patent Applications
Kateri A Ahrendt has submitted several notable patent applications. One of his latest applications is for "Imidazo [4,5-b] Pyridine Derivatives Used as Raf Inhibitors." This application details compounds of Formula I that are useful for the inhibition of Raf kinases. The methods described involve using these compounds, their stereoisomers, and pharmaceutically acceptable salts for the diagnosis, prevention, or treatment of various disorders in mammalian cells. Another significant application is for "N-(6-Aminopyridin-3-yl)-3-(Sulfonamido) Benzamide Derivatives as B-Raf Inhibitors for the Treatment of Cancer." This application also focuses on compounds of Formula I that inhibit Raf kinases and outlines methods for their use in treating associated pathological conditions.
Conclusion
Kateri A Ahrendt's work exemplifies the innovative spirit in the fight against cancer. His contributions to the development of Raf inhibitors highlight the importance of research in advancing medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile